Please assess the completion status of the following clinical trial:

Trial Title: 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a participant from Study 104RA202 (NCT 00664716)~* Stable dose of Methotrexate for the duration of the study~Exclusion Criteria:~* Participants with a significant change in their medical history from their previous BG9924 study~* Any clinically significant infectious illness or serious local infection~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 2 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol
- Group 1 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol
- Group 3 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol
- Group 4 (Type: EXPERIMENTAL): Drug: BG9924 - dose administered as per Biogen-Idec protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).